FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Teva Pharmaceuticals Mimvey Recall

Mimvey (estradiol and norethindrone acetate tablets USP), 1 mg/0

Teva Pharmaceuticals USA · Parsippany, NJ

Risk level
Class III
Reported by FDA
Feb 9, 2022
Recall ID
D-0521-2022
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Mimvey starting Jan 7, 2022. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0521-2022 on Feb 9, 2022. Reason: Mislabeling. Status: Terminated.

Why it was recalled

Mislabeling

Product description

Mimvey (estradiol and norethindrone acetate tablets USP), 1 mg/0.5 mg, packaged in cartons of 28 Tablets, Rx only, Manufactured By: Barr Laboratories, Inc., Pomona, NY 10970, Manufactured For: Teva Pharmaceuticals USA Inc. North Wales, PA 19454, NDC 0093-5455-28

Lot numbers, UPCs & expiration codes

Lot#: 100018611, Exp 03/2022; 100019834, Exp 06/2022; 100022226, Exp 09/2022; 100024574, Exp 01/2023

Where it was sold

USA Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0521-2022
Classification
Class III
Status
Terminated
Recall initiated
Jan 7, 2022
FDA report date
Feb 9, 2022
Quantity
218174 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA

Original FDA data

Every field from FDA enforcement report D-0521-2022, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
89368
Address
400 Interpace Pkwy
Code information
Lot#: 100018611, Exp 03/2022; 100019834, Exp 06/2022; 100022226, Exp 09/2022; 100024574, Exp 01/2023
Postal code
07054-1120
Report date
Feb 9, 2022
Product type
Drugs
Recall number
D-0521-2022
Classification
Class III
Recalling firm
Teva Pharmaceuticals USA
Product quantity
218174 cartons
Termination date
Jun 1, 2023
Reason for recall
Mislabeling
Voluntary / mandated
Voluntary: Firm initiated
Product description
Mimvey (estradiol and norethindrone acetate tablets USP), 1 mg/0.5 mg, packaged in cartons of 28 Tablets, Rx only, Manufactured By: Barr Laboratories, Inc., Pomona, NY 10970, Manufactured For: Teva Pharmaceuticals USA Inc. North Wales, PA 19454, NDC 0093-5455-28
Distribution pattern
USA Nationwide
Recall initiation date
Jan 7, 2022
Initial firm notification
Letter
Center classification date
Feb 2, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0521-2022, published Feb 9, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls